S. number Method/mobile phase Column/stationary phase Wavelength (nm) Retention time (min) Linearity range Application Reference number 1 RP-HPLC/acetonitrile: 0.025 M Isocratic ODS C18 (250 × 4.6 mm i.d., 5
m) column 318 5.637 5–40
g/mL Pharmaceutical dosage forms [3 ] 2 HPLC/20 mM potassium dihydrogen orthophosphate: acetonitrile (60 : 40) containing 0.1% Inertsil ODS 3V, (250 × 4.6 mm, 5
m) 318 5.4 0.05–15.00
g/mL Plasma samples [4 ] 4 HPTLC/chloroform-methanol, 10 + 0.5 (v/v) TLC aluminium plates precoated with silica gel 60F-254 317 — 200 and 1000 ng. STZ tablets [5 ] 5 HPTLC/toluene: acetonitrile (60 : 40, v/v) TLC aluminium plates precoated with silica gel 60F-254 314 — 100–500 ng/spot Bulk drug and formulations [6 ] 7 Spectrophotometric estimation: — Method A-320, Method B-290, and Method C-325—315 nm — 5–35
g/mL for Method A and 5–40
g/mL for Method B and Method C STZ tablet formulation [7 ] 9 Simultaneous estimation of Ofloxacin and STZ Kromasil C18 column (250 × 4.6 mm, 5
m) 318 Ofloxacin ~ 2.29 1.5 to 3.6
g/mL and 1.0 to 2.4
g/mL, STZ and Ofloxacin, respectively Ofloxacin and STZ tablets [8 ] 10 Simultaneous estimation of Ofloxacin and STZ HiQSil C18W (250 mm × 4.6 mm i.d., 5
m) 296 nm Ofloxacin-2.85 5–50
g/mL, STZ and Ofloxacin Ofloxacin and STZ tablets [9 ] 11 RP-HPLC/orthophosphoric acid buffer, pH 3: acetonitrile (60 : 40) (v/v) Hypersil C18 column (250 mm × 4.6 mm, 5
m) 320 nm 4.3 10 to 60 ppm Stability indicating method Present work
